

Ready to start planning your care? Call us at [646-926-0945](tel:646-926-0945) to make an appointment.

X



Memorial Sloan Kettering
Cancer Center

[Make an Appointment](#)

Back

Projects

[View All Projects](#)

[Learn About Cancer & Treatment](#)



ABOUT US

[Our mission, vision & core values](#)

[Leadership](#)

[History](#)

[Inclusion & belonging](#)

[Annual report](#)

[Give to MSK](#)

Leukemia

A Phase I Trial of Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated with Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19(CAR)

Investigator: Jae Park, MD

Co-Investigator: Craig Sauter, MD

A Phase I Trial of Consolidation Therapy with Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients with Chronic Lymphocytic Leukemia Following Upfront Chemotherapy with Pentostatin, Cyclophosphamide and Rituximab

Investigator: Jae Park, MD

Co-Investigator: Craig Sauter, MD; Andrew Zelenetz, MD, PhD

A Phase I Trial of Autologous T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients with relapsed B-Cell Acute Lymphoblastic Leukemia

Investigator: Kevin Curran, MD

Co-Investigator: Nancy Kernan, MD; Rachel Kobos, MD; Peter Steinherz, MD

A Phase I Dose Escalation Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the B-Cell Specific Antigen CD19 Positive Residual Or Relapsed Acute Lymphoblastic Leukemia After Allogeneic Hematopoietic Progenitor Cell Transplantation

Investigator: Kevin Curran, MD

Co-Investigator: Nancy Kernan, MD; Craig Sauter, MD

Lymphoma

A Phase I/IIa Trial For The Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

Investigator: Jae Park, MD

Co-Investigator: M. Lia Palomba, MD; Craig Sauter, MD

A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Investigator: Craig Sauter, MD

Co-Investigator: Jenna Goldberg, MD; Jae Park, MD

Lung Cancer, Breast Cancer and Mesothelioma

A Phase I Clinical Trial of Malignant Pleural Disease Treated with Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Investigator: Prasad S. Adusumilli, MD

Co-Investigator(s): Lee Krug, MD; Roisin O'Cearbhaill, MB BCh BAO

© 2026 Memorial Sloan Kettering Cancer Center